Alpine Immune Sciences Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Employees
  • 52
Employees
  • Stock Symbol
  • ALPN
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $9.84
  • (As of Friday Closing)

Alpine Immune Sciences General Information

Description

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing modern, protein-based immunotherapies targeting the immune synapse to treat cancer, inflammation, and other diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics capable of modulating human immune system proteins. Its product pipeline includes ALPN-101 and ALPN-202.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 188 East Blaine Street
  • 200
  • Seattle, WA 98102
  • United States
+1 (206) 000-0000

Alpine Immune Sciences Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Alpine Immune Sciences Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.84 $9.06 $2.05 - $15.00 $234M 23.8M 47K -$1.42

Alpine Immune Sciences Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 140,790 41,025 (6,340) 73,263
Revenue 4,576 1,740 705 1,731
EBITDA (26,908) (42,294) (37,442) (8,132)
Net Income (27,738) (41,852) (36,487) (7,783)
Total Assets 154,033 54,093 54,873 85,222
Total Debt 22,265 16,356 4,203 5,034
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alpine Immune Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alpine Immune Sciences‘s full profile, request access.

Request a free trial

Alpine Immune Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Alpine Immune Sciences‘s full profile, request access.

Request a free trial

Alpine Immune Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing mo
Pharmaceuticals
Seattle, WA
52 As of 2020
00000
00000000000 00000

000000

lore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui off
0000000000000
Monrovia, CA
000 As of 0000
00000
0000 0000-00-00
00000000 00000

00000000

pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit
0000000000000
Vancouver, Canada
000 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alpine Immune Sciences Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Xencor Formerly VC-backed Monrovia, CA 000 00000 00000000 00000
000000000 Formerly VC-backed Vancouver, Canada 000 00000 00000000 00000
000000000 00000000 Formerly VC-backed Tarrytown, NY 0000 00000 00000000000 00000
00000000 0000 Formerly VC-backed Austin, TX 00 00000 00000000 00000
00000000000 Formerly VC-backed Rockville, MD 000 00000 00000000000 00000
To view Alpine Immune Sciences’s complete competitors history, request access »

Alpine Immune Sciences Executive Team (9)

Name Title Board Seat Contact Info
Mitchell Gold MD Chief Executive Officer & Chairman
Stanford Peng Ph.D Executive & President
Paul Rickey Chief Financial Officer
Remy Durand Ph.D Senior Vice President of Business Development and Corporate Strategy
Wayne Gombotz Ph.D Chief Technology Officer
You’re viewing 5 of 9 executive team members. Get the full list »

Alpine Immune Sciences Board Members (9)

Name Representing Role Since
Christopher Peetz Self Board Member 000 0000
James Topper Ph.D Self Board Member 000 0000
Jay Venkatesan MD Self Board Member 000 0000
Mitchell Gold MD Alpine Immune Sciences Chief Executive Officer & Chairman 000 0000
Paul Sekhri Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Alpine Immune Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alpine Immune Sciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alpine Immune Sciences‘s full profile, request access.

Request a free trial

Alpine Immune Sciences Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 0000000000 25-Jul-2017 000000000000000000 0000 Biotechnology 00000000 0000 00
To view Alpine Immune Sciences’s complete acquisitions history, request access »